Showing 1 - 1 results of 1 for search 'Herbert Newton', query time: 0.02s Refine Results
  1. 1
    Endoglin inhibitor TRC105 with or without bevacizumab for bevacizumab-refractory glioblastoma (ENDOT): a multicenter phase II trial

    Endoglin inhibitor TRC105 with or without bevacizumab for bevacizumab-refractory glioblastoma (ENDOT): a multicenter phase II trial by Manmeet S. Ahluwalia, Lisa R. Rogers, Rekha Chaudhary, Herbert Newton, Ahmad Ozair, Atulya A. Khosla, Andrew B. Nixon, Bonne J. Adams, Ben K. Seon, David M. Peereboom, Charles P. Theuer

    Published 2023-09-01
    Get full text
    Article

Search Tools: